Clinical and Experimental Vaccine Research

The Korean Vaccine Society (대한백신학회)
권호 표지
DOI QR코드

DOI QR Code

Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador

  • Received : 2023.06.27
  • Accepted : 2023.10.20
  • Published : 2024.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The effectiveness of coronavirus disease 2019 (COVID-19) vaccination schemes and the combination of vaccines of various platforms for administering booster doses is still being studied since it will depend on the population's response to vaccines. We aimed to evaluate the safety, protection, and immunogenicity of the Salvadorean population's third dose booster COVID-19 vaccine and the potential benefit of homologous vs. heterologous regimens. Materials and Methods: This is an analytical observational cohort study in a population aged 18 to 65 years that was primarily vaccinated with AstraZeneca, Sinovac, or Pfizer/BioNTech. Volunteers were recruited (n=223) and followed up for 3 months after receiving the 3rd vaccine (BNT162b2) as a booster. Adverse reactions were monitored, serum anti-spike immunoglobulin G (IgG) was assessed by chemiluminescence, and a polymerase chain reaction was carried out when subjects developed clinical signs. Results: The cohorts finally included 199 participants, and we observed only mild adverse effects in all cohorts. A significant increase in specific IgG levels was found after the booster dose in all cohorts. The heterologous scheme with Sinovac showed the greatest increase in antibody titer, and a decrease was observed in all participants after 3 months. During the follow-up period, 30 participants showed symptomatology compatible with COVID-19, but only four were laboratory-confirmed and they showed mild clinical signs. Conclusion: These findings indicate that the booster doses used were safe and promoted an immediate increase in immunogenicity, which decreased over time. The heterologous regimen showed stronger immunogenicity compared to the messenger RNA-based homologous scheme.

Keywords

References

  1. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2021;21:39-51. https://doi.org/10.1016/S1473-3099(20)30831-8
  2. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021;19:141-54. https://doi.org/10.1038/s41579-020-00459-7
  3. Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020;396:479-88. https://doi.org/10.1016/S0140-6736(20)31605-6
  4. Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N Engl J Med 2021;385:1761-73. https://doi.org/10.1056/NEJMoa2110345
  5. El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med 2021;385:1774-85. https://doi.org/10.1056/NEJMoa2113017
  6. Falsey AR, Sobieszczyk ME, Hirsch I, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine. N Engl J Med 2021;385:2348-60. https://doi.org/10.1056/NEJMoa2105290
  7. Yu F, Tai W, Cheng G. T-cell immunity: a barrier to Omicron immune evasion. Signal Transduct Target Ther 2022;7:297.
  8. Wilhelm A, Widera M, Grikscheit K, et al. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies. MedRxiv [Preprint] 2021 Dec 7. https://doi.org/10.1101/2021.12.07.21267432
  9. Liu J, Chandrashekar A, Sellers D, et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature 2022;603:493-6. https://doi.org/10.1038/s41586-022-04465-y
  10. Pascuale CA, Varese A, Ojeda DS, et al. Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273. Cell Rep Med 2022;3:100706.
  11. Nunez NG, Schmid J, Power L, et al. High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity. Nat Immunol 2023;24:941-54. https://doi.org/10.1038/s41590-023-01499-w
  12. Bhandari B, Rayamajhi G, Lamichhane P, Shenoy AK. Adverse events following immunization with COVID-19 vaccines: a narrative review. Biomed Res Int 2022;2022:2911333.
  13. Abdel-Qader DH, Abdel-Qader H, Silverthorne J, et al. Active safety surveillance of four types of COVID-19 vaccines: a national study from Jordan. Clin Drug Investig 2022;42:813-27. https://doi.org/10.1007/s40261-022-01191-1
  14. Hause AM, Baggs J, Marquez P, et al. Safety monitoring of COVID-19 vaccine booster doses among adults: United States, September 22, 2021-February 6, 2022. MMWR Morb Mortal Wkly Rep 2022;71:249-54. https://doi.org/10.15585/mmwr.mm7107e1
  15. Menni C, May A, Polidori L, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. Lancet Infect Dis 2022;22:1002-10. https://doi.org/10.1016/S1473-3099(22)00146-3
  16. Alvear Cardona JS. Determination of anti-"S" protein antibodies against SARS-CoV-2, pre and post vaccination with the vaccine Bnt162b2 Pfizer-Biontech in volunteers [Internet]. Cordoba: Universidad de Cordoba; 2021 [cited 2023 Oct 10]. Available from: https://repositorio.unicordoba.edu.co/handle/ucordoba/4324
  17. Munive-Lima MR, Akle-Fierro D, Mendoza-Franco HM, Akle-Cantu D. Levels of IgG antibodies against spike protein of the SARSCoV-2 virus by chemiluminescence in vaccinated patients. Rev Mex Patol Clin Med Lab [Internet] 2022 [cited 2023 Oct 10];69:6-10. Available from: https://doi.org/10.35366/108002
  18. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27:1205-11. https://doi.org/10.1038/s41591-021-01377-8
  19. Israel A, Shenhar Y, Green I, et al. Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection. medRxiv [Preprint] 2021 Aug 21. https://doi.org/10.1101/2021.08.19.21262111
  20. Le T, Cherry JD, Chang SJ, et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis 2004;190:535-44. https://doi.org/10.1086/422035
  21. Wang Z, An J, Liu K, et al. A potent, broadly protective vaccine against SARS-CoV-2 variants of concern. NPJ Vaccines 2022;7:144.
  22. Fowlkes A, Gaglani M, Groover K, et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (Delta) variant predominance: eight U.S. locations, December 2020-August 2021. MMWR Morb Mortal Wkly Rep 2021;70:1167-9. https://doi.org/10.15585/mmwr.mm7034e4